Ultrasound Enhanced Thrombolysis for Stroke

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Spontaneous arterial recanalization occurs at a rate of 6% per hour, and it can be doubled with intravenous tissue plasminogen activator (TPA) therapy since early dramatic clinical improvement, a substitute for early thrombus break-up, occurs in TPA-treated patients. TPA activity can be enhanced with ultrasound including 2-MHz transcranial Doppler (TCD). TCD identifies residual blood flow signals around thrombi, and, by delivering mechanical pressure waves, exposes more thrombus surface to circulating TPA. In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 2 hours after TPA bolus occurred in 25% of patients treated with TPA+TCD compared with 8% who received TPA alone (P = 0.02). Complete clearance of a thrombus and dramatic recovery of brain function during treatment are feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain perfusion seen in the Target CLOTBUST group resulted in a trend of 13% more patients achieving favorable outcome at 3 months, thus providing the rationale for a pivotal trial. The ability of TPA to break up thrombi can be further enhanced with harmless diagnostic ultrasound contrast agents. Current ongoing clinical trials include phase II studies of 2-MHz TCD with ultrasound contrast agents, or microbubbles: TCD+TPA+Levovist; TCD+TPA+MRX nano-platform (C3F8 ImaRx). Intraarterial ultrasound-enhanced TPA delivery is tested in the Interventional Management of Stroke (IMS) clinical trial using 1.7- to 2.1-MHz pulsed-wave ultrasound catheter (EKOS). Dose escalation studies of microbubbles, ultrasound exposure, and the development of an operator-independent ultrasound device are currently underway.

Original languageEnglish (US)
Pages (from-to)106-110
Number of pages5
JournalSeminars in Cerebrovascular Diseases and Stroke
Volume5
Issue number2
DOIs
StatePublished - Jun 1 2005

Fingerprint

Tissue Plasminogen Activator
Stroke
Thrombosis
Microbubbles
Contrast Media
Doppler Ultrasonography
Phase II Clinical Trials
Recovery of Function
Brain
Ultrasonography
Catheters
Perfusion
Clinical Trials
Pressure
Equipment and Supplies

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Ultrasound Enhanced Thrombolysis for Stroke. / Alexandrov, Andrei.

In: Seminars in Cerebrovascular Diseases and Stroke, Vol. 5, No. 2, 01.06.2005, p. 106-110.

Research output: Contribution to journalArticle

@article{116845e839e4435da6883de817095fab,
title = "Ultrasound Enhanced Thrombolysis for Stroke",
abstract = "Spontaneous arterial recanalization occurs at a rate of 6{\%} per hour, and it can be doubled with intravenous tissue plasminogen activator (TPA) therapy since early dramatic clinical improvement, a substitute for early thrombus break-up, occurs in TPA-treated patients. TPA activity can be enhanced with ultrasound including 2-MHz transcranial Doppler (TCD). TCD identifies residual blood flow signals around thrombi, and, by delivering mechanical pressure waves, exposes more thrombus surface to circulating TPA. In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 2 hours after TPA bolus occurred in 25{\%} of patients treated with TPA+TCD compared with 8{\%} who received TPA alone (P = 0.02). Complete clearance of a thrombus and dramatic recovery of brain function during treatment are feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain perfusion seen in the Target CLOTBUST group resulted in a trend of 13{\%} more patients achieving favorable outcome at 3 months, thus providing the rationale for a pivotal trial. The ability of TPA to break up thrombi can be further enhanced with harmless diagnostic ultrasound contrast agents. Current ongoing clinical trials include phase II studies of 2-MHz TCD with ultrasound contrast agents, or microbubbles: TCD+TPA+Levovist; TCD+TPA+MRX nano-platform (C3F8 ImaRx). Intraarterial ultrasound-enhanced TPA delivery is tested in the Interventional Management of Stroke (IMS) clinical trial using 1.7- to 2.1-MHz pulsed-wave ultrasound catheter (EKOS). Dose escalation studies of microbubbles, ultrasound exposure, and the development of an operator-independent ultrasound device are currently underway.",
author = "Andrei Alexandrov",
year = "2005",
month = "6",
day = "1",
doi = "10.1053/j.scds.2005.12.004",
language = "English (US)",
volume = "5",
pages = "106--110",
journal = "Seminars in Cerebrovascular Diseases and Stroke",
issn = "1528-9931",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Ultrasound Enhanced Thrombolysis for Stroke

AU - Alexandrov, Andrei

PY - 2005/6/1

Y1 - 2005/6/1

N2 - Spontaneous arterial recanalization occurs at a rate of 6% per hour, and it can be doubled with intravenous tissue plasminogen activator (TPA) therapy since early dramatic clinical improvement, a substitute for early thrombus break-up, occurs in TPA-treated patients. TPA activity can be enhanced with ultrasound including 2-MHz transcranial Doppler (TCD). TCD identifies residual blood flow signals around thrombi, and, by delivering mechanical pressure waves, exposes more thrombus surface to circulating TPA. In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 2 hours after TPA bolus occurred in 25% of patients treated with TPA+TCD compared with 8% who received TPA alone (P = 0.02). Complete clearance of a thrombus and dramatic recovery of brain function during treatment are feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain perfusion seen in the Target CLOTBUST group resulted in a trend of 13% more patients achieving favorable outcome at 3 months, thus providing the rationale for a pivotal trial. The ability of TPA to break up thrombi can be further enhanced with harmless diagnostic ultrasound contrast agents. Current ongoing clinical trials include phase II studies of 2-MHz TCD with ultrasound contrast agents, or microbubbles: TCD+TPA+Levovist; TCD+TPA+MRX nano-platform (C3F8 ImaRx). Intraarterial ultrasound-enhanced TPA delivery is tested in the Interventional Management of Stroke (IMS) clinical trial using 1.7- to 2.1-MHz pulsed-wave ultrasound catheter (EKOS). Dose escalation studies of microbubbles, ultrasound exposure, and the development of an operator-independent ultrasound device are currently underway.

AB - Spontaneous arterial recanalization occurs at a rate of 6% per hour, and it can be doubled with intravenous tissue plasminogen activator (TPA) therapy since early dramatic clinical improvement, a substitute for early thrombus break-up, occurs in TPA-treated patients. TPA activity can be enhanced with ultrasound including 2-MHz transcranial Doppler (TCD). TCD identifies residual blood flow signals around thrombi, and, by delivering mechanical pressure waves, exposes more thrombus surface to circulating TPA. In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 2 hours after TPA bolus occurred in 25% of patients treated with TPA+TCD compared with 8% who received TPA alone (P = 0.02). Complete clearance of a thrombus and dramatic recovery of brain function during treatment are feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain perfusion seen in the Target CLOTBUST group resulted in a trend of 13% more patients achieving favorable outcome at 3 months, thus providing the rationale for a pivotal trial. The ability of TPA to break up thrombi can be further enhanced with harmless diagnostic ultrasound contrast agents. Current ongoing clinical trials include phase II studies of 2-MHz TCD with ultrasound contrast agents, or microbubbles: TCD+TPA+Levovist; TCD+TPA+MRX nano-platform (C3F8 ImaRx). Intraarterial ultrasound-enhanced TPA delivery is tested in the Interventional Management of Stroke (IMS) clinical trial using 1.7- to 2.1-MHz pulsed-wave ultrasound catheter (EKOS). Dose escalation studies of microbubbles, ultrasound exposure, and the development of an operator-independent ultrasound device are currently underway.

UR - http://www.scopus.com/inward/record.url?scp=33646357482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646357482&partnerID=8YFLogxK

U2 - 10.1053/j.scds.2005.12.004

DO - 10.1053/j.scds.2005.12.004

M3 - Article

VL - 5

SP - 106

EP - 110

JO - Seminars in Cerebrovascular Diseases and Stroke

JF - Seminars in Cerebrovascular Diseases and Stroke

SN - 1528-9931

IS - 2

ER -